Cancer immunotherapy and diabete

ULB Center for Diabetes Research explains how Type 1 Diabete may be induced by immunotherapy

Antibodies targeting PD-1 and its ligand PDL1 are used in cancer immunotherapy but may lead to autoimmune diseases, including type 1 diabetes (T1D). The team of Pr Eizirik, colleagues from ULB found that PDL1 was present in insulin-positive cells from T1D individuals but absent from the islets of non-diabetic people. Interferons-α and -γ induced PDL1 expression in human islet cells. These findings indicate that PDL1 is expressed in beta cells from people with T1D, possibly to attenuate the autoimmune assault, and that it is induced by both type I and II interferons via IRF1.